{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T01:36:53Z","timestamp":1792201013689,"version":"4.4.0"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1097\/jcp.0000000000000070","type":"journal-article","created":{"date-parts":[[2014,2,13]],"date-time":"2014-02-13T11:17:15Z","timestamp":1392290235000},"page":"256-260","source":"Crossref","is-referenced-by-count":47,"title":["The Influence of the CYP3A4*22 Polymorphism on Serum Concentration of Quetiapine in Psychiatric Patients"],"prefix":"10.1097","volume":"34","author":[{"given":"Karen","family":"van der Weide","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"van der Weide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"suppl 2","key":"R1-14-20210128","first-page":"10","article-title":"Management of nonresponse and intolerance: switching strategies.","volume":"61","author":"Fava","year":"2000","journal-title":"J Clin Psychiatry"},{"key":"R2-14-20210128","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/00008571-200007000-00001","article-title":"Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method.","volume":"10","author":"Ozdemir","year":"2000","journal-title":"Pharmacogenetics"},{"key":"R3-14-20210128","doi-asserted-by":"crossref","first-page":"561","DOI":"10.2174\/1389200023337054","article-title":"The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans.","volume":"3","author":"Danielson","year":"2002","journal-title":"Curr Drug Metab"},{"key":"R4-14-20210128","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/S0169-409X(02)00066-2","article-title":"Genetic contribution to variable human CYP3A-mediated metabolism.","volume":"54","author":"Lamba","year":"2002","journal-title":"Adv Drug Deliv Rev"},{"key":"R5-14-20210128","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0022-3565(25)22379-5","article-title":"Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians.","volume":"270","author":"Shimada","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"R6-14-20210128","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1124\/dmd.31.6.755","article-title":"Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism.","volume":"31","author":"Westlind-Johnsson","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"R7-14-20210128","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1177\/0091270003256059","article-title":"Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juice.","volume":"43","author":"Veronese","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"R8-14-20210128","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2217\/14622416.8.5.443","article-title":"Sex-dependent genetic markers of CYP3A4 expression and activity in human liver microsomes.","volume":"8","author":"Schirmer","year":"2007","journal-title":"Pharmacogenomics"},{"key":"R9-14-20210128","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1440-1746.1996.tb00007.x","article-title":"Influence of clinicopathological variables on CYP protein expression in human liver.","volume":"11","author":"George","year":"1996","journal-title":"J Gastroenterol Hepatol"},{"key":"R10-14-20210128","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1365-2125.2005.02507.x","article-title":"Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics.","volume":"61","author":"Grimm","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"R11-14-20210128","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1592\/phco.29.11.1386","article-title":"Clinically significant adverse events from a drug interaction between quetiapine and atazanavir-ritonavir in two patients.","volume":"29","author":"Pollack","year":"2009","journal-title":"Pharmacotherapy"},{"key":"R12-14-20210128","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1034\/j.1600-0447.2001.00299.x","article-title":"CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages.","volume":"104","author":"Kirchheiner","year":"2001","journal-title":"Acta Psychiatr Scand"},{"key":"R13-14-20210128","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/sj.clpt.6100507","article-title":"Pharmacogenetics: from bench to byte.","volume":"83","author":"Swen","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"R14-14-20210128","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/clpt.2011.34","article-title":"Pharmacogenetics: from bench to bytean update of guidelines.","volume":"89","author":"Swen","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"R15-14-20210128","doi-asserted-by":"crossref","first-page":"795","DOI":"10.2217\/bmm.11.94","article-title":"From pharmacogenomic knowledge acquisition to clinical applications: the PharmGKB as a clinical pharmacogenomic biomarker resource.","volume":"5","author":"McDonagh","year":"2011","journal-title":"Biomark Med"},{"key":"R17-14-20210128","first-page":"23","article-title":"CYP3A4, CYP3A5 and MDR-1 variant alleles in the Dutch Caucasian population.","volume":"192","author":"van Schaik","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"R18-14-20210128","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/00008571-200203000-00006","article-title":"Common allelic variants of cytochrome P4503A4 and their prevalence in different populations.","volume":"12","author":"Lamba","year":"2002","journal-title":"Pharmacogenetics"},{"key":"R19-14-20210128","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1067\/mcp.2002.121371","article-title":"CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity.","volume":"71","author":"Garcia-Martin","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"R20-14-20210128","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/tpj.2010.28","article-title":"Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs.","volume":"11","author":"Wang","year":"2011","journal-title":"Pharmacogenomics J"},{"key":"R21-14-20210128","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1097\/FPC.0b013e32834c6edb","article-title":"Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study.","volume":"21","author":"Elens","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"R22-14-20210128","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/FPC.0b013e328351f3c1","article-title":"The new CYP3A4 intron 6 CT polymorphism (CYP3A422) is associated with an increased risk of delayed graft function and worse renal function in cyclosporine-treated kidney transplant patients.","volume":"22","author":"Elens","year":"2012","journal-title":"Pharmacogenet Genomics"},{"key":"R23-14-20210128","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.2217\/pgs.11.90","article-title":"Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors dose requirements and trough blood levels in stable renal transplant patients.","volume":"12","author":"Elens","year":"2011","journal-title":"Pharmacogenomics"},{"key":"R24-14-20210128","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1373\/clinchem.2011.165613","article-title":"A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients.","volume":"57","author":"Elens","year":"2011","journal-title":"Clin Chem"},{"key":"R25-14-20210128","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.jpeds.2012.11.031","article-title":"Fluticasone propionate pharmacogenetics: CYP3A422 polymorphism and pediatric asthma control.","volume":"162","author":"Stockmann","year":"2013","journal-title":"J Pediatr"},{"key":"R26-14-20210128","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1515\/DMDI.2006.21.3-4.187","article-title":"In vitro studies on quetiapine metabolism using the substrate depletion approach with focus on drug-drug interactions.","volume":"21","author":"Hasselstrom","year":"2006","journal-title":"Drug Metabol Drug Interact"},{"key":"R27-14-20210128","doi-asserted-by":"crossref","first-page":"509","DOI":"10.2165\/00003088-200140070-00003","article-title":"Clinical pharmacokinetics of quetiapine: an atypical antipsychotic.","volume":"40","author":"DeVane","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"R28-14-20210128","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1038\/sj.npp.1301646","article-title":"N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapines antidepressant activity.","volume":"33","author":"Jensen","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"R29-14-20210128","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1177\/0269881110389208","article-title":"Cytochrome P450 and ABCB1 genetics: association with quetiapine and norquetiapine plasma and cerebrospinal fluid concentrations and with clinical response in patients suffering from schizophrenia. A pilot study.","volume":"25","author":"Nikisch","year":"2011","journal-title":"J Psychopharmacol"},{"key":"R30-14-20210128","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1089\/cap.2007.0084","article-title":"Steady-state pharmacokinetic, safety, and tolerability profiles of quetiapine, norquetiapine, and other quetiapine metabolites in pediatric and adult patients with psychotic disorders.","volume":"18","author":"Winter","year":"2008","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R32-14-20210128","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/01.yic.0000188213.46667.f1","article-title":"Influence of age, gender, body weight and valproate comedication on quetiapine plasma concentrations.","volume":"21","author":"Aichhorn","year":"2006","journal-title":"Int Clin Psychopharmacol"},{"key":"R33-14-20210128","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1177\/0091270006293754","article-title":"Therapeutic drug monitoring of antidepressants and cytochrome p450 genotyping in general practice.","volume":"46","author":"Kootstra-Ros","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"R34-14-20210128","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/00007691-200410000-00005","article-title":"Quetiapine serum concentrations in psychiatric patients: the influence of comedication.","volume":"26","author":"Hasselstrom","year":"2004","journal-title":"Ther Drug Monit"},{"key":"R35-14-20210128","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2165\/00002018-200023040-00003","article-title":"Quetiapine: a review of its safety in the management of schizophrenia.","volume":"23","author":"Dev","year":"2000","journal-title":"Drug Saf"},{"key":"R36-14-20210128","first-page":"1526","article-title":"A significant drug-metabolizing role for CYP3A5 Drug Metab D","volume":"31","author":"Williams","year":"2003","journal-title":"ispos"},{"key":"R37-14-20210128","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/86882","article-title":"Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression.","volume":"27","author":"Kuehl","year":"2001","journal-title":"Nat Genet"},{"key":"R38-14-20210128","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1124\/dmd.108.023291","article-title":"Metabolism of quetiapine by CYP3A4 and CYP3A5 in presence or absence of cytochrome B5.","volume":"37","author":"Bakken","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"R39-14-20210128","first-page":"17","article-title":"The influence of cytochrome P450 pharmacogenetics on disposition of common antidepressant and antipsychotic medications.","volume":"27","author":"van der Weide","year":"2006","journal-title":"Clin Biochem Rev"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JCP.0000000000000070","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T21:09:35Z","timestamp":1746133775000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004714-201404000-00014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0000000000000070","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]}}}